Bone marrow aspirate or biopsy for multiple myeloma: when percentages matter!-Reference-Cited by-同舟云学术

Bone marrow aspirate or biopsy for multiple myeloma: when percentages matter!

Published:2024-07-27 Issue:9 Volume:17 Page:543-546
ISSN:1747-4086
Container-title:Expert Review of Hematology
language:en
Short-container-title:Expert Review of Hematology

Author:

Gjelberg Hilde K.¹,Helgeland Lars¹²,Tsykunova Galina³⁴⁵,Reikvam Håkon²³⁶

Affiliation:

1. Department of Pathology, Haukeland University Hospital, Bergen, Norway

2. Department of Medical Science, University of Bergen, Bergen, Norway

3. Department of Medicine, Haukeland University Hospital, Bergen, Norway

4. Department of Medicine, Hematology-Oncology and Research, Østfold Hospital Trust, Kalnes, Norway

5. Institute of Clinical Medicine, University of Oslo, Oslo, Norway

6. K.G. Jebsen Center for Myeloid Blood Cancer, Department of Clinical Science, University of Bergen, Bergen, Norway

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/17474086.2024.2383395

Reference22 articles.

1. Kumar SM, Baughn LB, et al. Plasma cell myeloma/multiple myeloma. In: WHO classification of tumours editorial board. Haematolymphoid tumours [internet]. Lyon (France): International Agency for Research on Cancer; 2024 [cited 2024 Mar 24]. (WHO classification of tumours series, 5th ed. vol. 11). https://tumourclassification.iarc.who.int/chapters/63

2. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

3. Smoldering multiple myeloma current treatment algorithms

4. Combined evaluation of bone marrow aspirate and biopsy is superior in the prognosis of multiple myeloma

5. Discrepancies between the percentage of plasma cells in bone marrow aspiration and BM biopsy: Impact on the revised IMWG diagnostic criteria of multiple myeloma